Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free CCM Stock Alerts

Concord Medical Services (CCM) Financials

Concord Medical Services logo
$4.54 -0.07 (-1.41%)
Closing price 07/29/2026 03:58 PM Eastern
Extended Trading
$4.46 -0.07 (-1.54%)
As of 07/29/2026 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Concord Medical Services

Annual Income Statements for Concord Medical Services

This table shows Concord Medical Services' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -12 -38 -44 -34 -44 -48 -43 -71 -42 -42 -13
Consolidated Net Income / (Loss)		 -12 -38 -44 -38 -51 -62 -82 -111 -75 -89 -54
Net Income / (Loss) Continuing Operations		 -12 -38 -44 -38 -51 -62 -82 -111 -75 -89 -54
Total Pre-Tax Income 		-0.80 -29 -39 -33 -56 -68 -83 -122 -78 -92 -53
Total Operating Income		 -0.87 -24 -33 -44 -63 -49 -72 -76 -65 -73 -37
Total Gross Profit		 40 24 15 2.88 -2.27 2.01 -8.93 -22 -11 -11 3.69
Total Revenue		 94 65 51 28 28 34 76 69 76 53 66
Operating Revenue		 94 65 51 28 28 34 76 68 76 53 66
Total Cost of Revenue		 54 41 36 25 31 32 85 91 86 63 62
Operating Cost of Revenue		 54 41 36 25 31 32 85 91 86 63 62
Total Operating Expenses		 41 48 48 46 61 51 63 54 54 62 41
Selling, General & Admin Expense		 37 40 43 46 50 49 63 54 54 62 38
Impairment Charge		 3.52 8.76 4.39 0.79 11 1.31 0.00 - 0.00 0.00 3.17
Total Other Income / (Expense), net		 0.07 -5.26 -6.45 11 6.64 -19 -11 -46 -13 -19 -16
Interest Expense		 14 13 14 6.73 4.12 13 12 17 23 26 22
Interest & Investment Income		 3.42 4.01 1.85 6.03 0.59 3.43 3.78 4.01 9.74 3.64 6.74
Other Income / (Expense), net		 10 3.54 5.50 11 10 -10 -3.32 -32 0.56 4.00 -0.96
Income Tax Expense		 11 8.67 4.88 4.96 -5.60 -5.79 -1.03 -10 -3.46 -2.40 0.87
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.15 -0.46 -0.21 -3.55 -6.47 -14 -39 -40 -33 -47 -41
Basic Earnings per Share		 ($0.58) ($2.00) ($2.19) ($2.76) ($4.24) ($5.11) ($6.26) ($0.54) ($0.32) ($0.32) ($0.01)
Weighted Average Basic Shares Outstanding		 134.55M 130.63M 130.09M 130.10M 130.24M 131.05M 131.05M 131.05M 131.05M 131.05M 131.05M
Diluted Earnings per Share		 ($0.58) ($2.00) ($2.19) ($2.76) ($4.24) ($5.11) ($6.26) ($0.54) ($0.32) ($0.32) ($0.01)
Weighted Average Diluted Shares Outstanding		 134.55M 130.63M 130.09M 130.10M 130.24M 131.05M 131.05M 131.05M 131.05M 131.05M 131.05M
Weighted Average Basic & Diluted Shares Outstanding		 134.55M 130.63M 130.09M 130.10M 130.24M 131.05M 131.05M 260.50M 260.50M 260.50M 260.50M

Quarterly Income Statements for Concord Medical Services

No quarterly income statements for Concord Medical Services are available.

Annual Cash Flow Statements for Concord Medical Services

This table details how cash moves in and out of Concord Medical Services' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.03 -40 -7.39 24 -108 57 -45 0.06 -9.71 20 8.83
Net Cash From Operating Activities		 -27 -11 4.10 -5.62 -28 -35 -56 -31 -39 -54 -29
Net Cash From Continuing Operating Activities		 -27 -11 6.10 -5.62 -28 -35 -56 -31 -39 -54 -29
Net Income / (Loss) Continuing Operations		 -12 -38 -44 -38 -51 -62 -82 -111 -75 -89 -54
Consolidated Net Income / (Loss)		 -12 -38 -44 -38 -51 -62 -82 -111 -75 -89 -54
Depreciation Expense		 21 17 13 5.95 6.37 8.46 10 13 12 12 15
Amortization Expense		 3.09 1.71 1.76 2.00 3.08 3.89 6.24 6.40 6.53 6.30 6.54
Non-Cash Adjustments To Reconcile Net Income		 -54 14 23 1.59 24 22 15 56 27 40 19
Changes in Operating Assets and Liabilities, net		 15 -5.92 12 23 -11 -7.07 -5.55 4.81 -9.58 -23 -15
Net Cash From Investing Activities		 -60 -11 -48 -146 -154 -82 -89 -17 -6.72 -81 7.72
Net Cash From Continuing Investing Activities		 -60 -11 -43 -146 -154 -82 -89 -17 -6.72 -81 7.72
Purchase of Property, Plant & Equipment		 -28 -12 -15 -111 -101 -78 -119 -56 -16 -55 -13
Acquisitions		 -43 3.62 -15 -79 -60 -27 -12 -0.45 -0.59 -15 -0.00
Purchase of Investments		 -9.13 -26 -7.67 -37 0.00 -17 -1.01 0.00 -0.01 -28 19
Sale of Property, Plant & Equipment		 0.16 1.71 5.85 16 9.95 0.04 33 0.82 0.04 0.00 1.07
Sale and/or Maturity of Investments		 3.70 9.95 0.96 31 7.18 0.00 5.62 2.47 10 5.16 0.00
Other Investing Activities, net		 4.10 9.90 -14 2.85 -11 2.72 4.95 36 0.00 12 0.45
Net Cash From Financing Activities		 90 -17 29 175 74 175 101 56 36 157 28
Net Cash From Continuing Financing Activities		 90 -17 29 175 74 175 101 56 36 157 28
Repayment of Debt		 -61 -140 -62 -199 -100 -195 -33 -57 -63 -240 -124
Issuance of Debt		 148 74 88 175 175 246 80 93 63 332 65
Issuance of Common Equity		 0.00 20 0.00 218 0.00 108 63 0.00 0.00 70 72
Other Financing Activities, net		 6.20 75 25 -19 -1.43 17 -9.34 20 37 -4.77 16
Effect of Exchange Rate Changes		 -2.65 -1.61 0.02 0.07 0.17 -0.39 -0.73 -6.84 -0.34 -1.13 1.77
Cash Interest Paid		 8.23 12 14 8.66 9.22 11 21 21 21 26 26
Cash Income Taxes Paid		 7.42 8.69 3.31 5.32 2.48 0.50 0.00 0.44 0.13 0.02 0.02

Quarterly Cash Flow Statements for Concord Medical Services

No quarterly cash flow statements for Concord Medical Services are available.

Annual Balance Sheets for Concord Medical Services

This table presents Concord Medical Services' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 547 463 532 667 617 820 978 871 853 922 936
Total Current Assets		 229 171 170 179 41 104 92 110 87 135 135
Cash & Equivalents		 74 27 15 59 11 51 25 23 8.19 30 43
Restricted Cash		 85 74 87 61 - 0.72 0.22 0.15 4.55 2.84 0.13
Short-Term Investments		 25 8.47 2.90 7.28 - - - - 0.00 18 0.00
Accounts Receivable		 33 27 20 13 11 12 20 19 10 7.01 6.30
Inventories, net		 0.59 0.85 0.96 0.49 0.62 3.32 5.98 12 5.68 4.58 6.57
Prepaid Expenses		 12 23 41 33 14 33 40 56 58 72 79
Plant, Property, & Equipment, net		 140 111 122 177 273 394 494 473 500 507 533
Total Noncurrent Assets		 179 180 239 311 304 323 392 288 266 279 269
Long-Term Investments		 39 59 116 57 9.32 53 61 63 56 65 60
Goodwill		 - - 0.00 24 30 33 91 83 81 78 82
Intangible Assets		 6.62 2.46 1.20 66 76 80 103 51 46 40 37
Other Noncurrent Operating Assets		 112 108 114 158 184 154 136 90 84 96 90
Total Liabilities & Shareholders' Equity		 547 463 532 667 617 820 978 871 853 922 936
Total Liabilities		 329 286 376 336 346 451 547 578 607 700 672
Total Current Liabilities		 229 136 170 127 90 79 126 163 275 291 279
Short-Term Debt		 140 92 109 64 47 23 47 74 147 141 140
Accounts Payable		 0.12 0.29 0.70 0.79 1.19 2.87 16 21 18 27 17
Accrued Expenses		 35 40 59 61 40 51 60 61 103 116 115
Current Deferred & Payable Income Tax Liabilities		 10 3.46 0.92 0.55 0.11 0.13 0.00 0.12 0.21 0.22 1.08
Other Current Liabilities		 - - - 0.00 1.85 2.10 3.21 5.21 6.55 6.23 6.00
Total Noncurrent Liabilities		 99 150 206 210 256 372 421 416 332 409 392
Long-Term Debt		 92 67 80 72 185 303 342 358 281 369 353
Noncurrent Deferred & Payable Income Tax Liabilities		 7.73 7.12 11 24 24 24 29 16 14 11 11
Other Noncurrent Operating Liabilities		 - 76 61 81 46 46 50 41 37 28 29
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 218 177 156 81 -2.92 -79 -147 292 246 222 265
Total Preferred & Common Equity		 212 167 143 64 -18 -102 -215 -270 -299 -312 -301
Total Common Equity		 212 167 143 64 -18 -102 -215 -270 -299 -312 -301
Common Stock		 270 266 286 256 253 283 304 280 283 297 349
Retained Earnings		 -51 -86 -135 -179 -256 -378 -514 -546 -572 -599 -639
Treasury Stock		 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00
Accumulated Other Comprehensive Income / (Loss)		 -7.09 -13 -7.28 -13 -14 -7.14 -4.63 -4.03 -9.21 -11 -11
Noncontrolling Interest		 6.43 9.41 12 17 15 23 68 562 545 534 565

Quarterly Balance Sheets for Concord Medical Services

No quarterly balance sheets for Concord Medical Services are available.

Annual Metrics And Ratios for Concord Medical Services

This table displays calculated financial ratios and metrics derived from Concord Medical Services' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 132,994,201.00 130,091,977.00 130,091,977.00 130,178,377.00 130,241,995.00 130,251,685.00 260,503,370.00 260,503,370.00 260,503,370.00 260,503,370.00 260,503,370.00
DEI Adjusted Shares Outstanding		 13,299,420.00 13,009,198.00 13,009,198.00 13,017,838.00 13,024,199.00 13,025,168.00 26,050,337.00 26,050,337.00 26,050,337.00 260,503,370.00 260,503,370.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.90 -2.89 -3.35 -2.63 -3.38 -3.66 -1.64 -2.73 -1.61 -0.16 -0.05
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -3.82% -30.48% -22.16% -45.29% 2.50% 20.44% 122.16% -9.98% 10.35% -30.51% 25.19%
EBITDA Growth		 -49.03% -106.39% -481.59% -93.47% -78.84% -7.71% -26.70% -51.47% 47.81% -9.51% 66.65%
EBIT Growth		 -71.69% -318.13% -30.83% -18.81% -63.98% -11.84% -27.86% -44.18% 40.40% -6.57% 44.34%
NOPAT Growth		 -103.84% -2,665.35% -34.45% -33.98% -44.15% 22.59% -47.98% -5.85% 14.34% -11.80% 48.71%
Net Income Growth		 -162.41% -214.91% -15.33% 13.91% -33.94% -22.93% -31.99% -35.94% 32.92% -19.44% 39.27%
EPS Growth		 -163.04% -244.83% -9.50% -26.03% -53.62% -20.52% -22.50% -35.94% 32.92% -0.69% 95.56%
Operating Cash Flow Growth		 66.18% 58.01% 136.64% -236.94% -399.33% -26.00% -59.55% 44.28% -23.94% -39.94% 47.04%
Free Cash Flow Firm Growth		 -125.35% 276.45% -143.21% -305.98% -25.98% 34.09% -39.12% 121.03% -129.33% -419.26% -2.88%
Invested Capital Growth		 24.52% -41.35% 11.65% 77.04% 53.07% 21.81% 24.40% -12.84% -5.27% 1.84% 6.13%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 42.69% 37.03% 29.61% 10.35% -7.98% 5.87% -11.72% -32.22% -14.26% -20.62% 5.61%
EBITDA Margin		 35.77% -3.29% -24.56% -86.87% -151.57% -135.55% -77.30% -130.08% -61.52% -96.93% -25.83%
Operating Margin		 -0.93% -37.06% -64.01% -156.76% -220.45% -141.70% -94.38% -110.98% -86.15% -138.60% -56.78%
EBIT Margin		 10.08% -31.64% -53.18% -115.48% -184.74% -171.56% -98.74% -158.15% -85.42% -130.99% -58.24%
Profit (Net Income) Margin		 -12.86% -58.25% -86.32% -135.83% -177.50% -181.17% -107.64% -162.54% -98.81% -169.83% -82.39%
Tax Burden Percent		 1,508.93% 129.56% 112.52% 115.12% 90.03% 91.48% 98.76% 91.56% 95.58% 97.39% 101.62%
Interest Burden Percent		 -8.45% 142.12% 144.25% 102.17% 106.72% 115.44% 110.38% 112.25% 121.03% 133.13% 139.22%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -0.25% -7.83% -13.45% -12.33% -10.99% -6.34% -7.61% -7.77% -7.34% -8.35% -4.12%
ROIC Less NNEP Spread (ROIC-NNEP)		 141.90% -119.83% -702.37% -194.14% -17.66% -19.34% -19.73% -25.69% -15.59% -18.51% -11.28%
Return on Net Nonoperating Assets (RNNOA)		 -4.51% -11.42% -12.93% -3.18% -5.80% -13.06% -12.90% -23.08% -20.45% -29.85% -18.20%
Return on Equity (ROE)		 -4.75% -19.25% -26.38% -15.51% -16.79% -19.40% -20.51% -30.85% -27.79% -38.20% -22.32%
Cash Return on Invested Capital (CROIC)		 -22.09% 44.29% -24.46% -67.94% -52.93% -26.00% -29.36% 5.95% -1.92% -10.18% -10.07%
Operating Return on Assets (OROA)		 1.85% -4.09% -5.43% -5.35% -8.19% -8.19% -8.37% -11.74% -7.50% -7.77% -4.13%
Return on Assets (ROA)		 -2.36% -7.53% -8.81% -6.29% -7.87% -8.65% -9.12% -12.06% -8.68% -10.07% -5.84%
Return on Common Equity (ROCE)		 -4.69% -18.48% -24.65% -6.60% -1.28% 3.62% 8.13% 20.71% 29.38% 49.93% 28.15%
Return on Equity Simple (ROE_SIMPLE)		 -5.70% -22.73% -30.59% -59.28% 286.80% 60.94% 38.15% 41.26% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.61 -17 -23 -30 -44 -34 -50 -53 -46 -51 -26
NOPAT Margin		 -0.65% -25.94% -44.81% -109.73% -154.32% -99.19% -66.07% -77.69% -60.31% -97.02% -39.75%
Net Nonoperating Expense Percent (NNEP)		 -142.15% 112.00% 688.92% 181.81% 6.68% 13.00% 12.12% 17.92% 8.25% 10.16% 7.16%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -7.35% -6.78% -6.97% -3.46%
Cost of Revenue to Revenue		 57.31% 62.97% 70.39% 89.65% 107.98% 94.13% 111.73% 132.00% 114.26% 120.62% 94.39%
SG&A Expenses to Revenue		 39.87% 60.65% 84.98% 164.26% 174.11% 143.75% 82.67% 78.77% 71.90% 117.98% 57.58%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 43.62% 74.09% 93.62% 167.11% 212.47% 147.56% 82.67% 78.77% 71.90% 117.98% 62.39%
Earnings before Interest and Taxes (EBIT)		 9.46 -21 -27 -32 -53 -59 -75 -108 -65 -69 -38
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 34 -2.15 -12 -24 -43 -46 -59 -89 -47 -51 -17
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.03 1.22 1.01 2.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 1.06 1.24 1.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.32 3.12 2.84 5.56 4.06 3.47 1.14 2.08 1.26 0.89 5.09
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 20.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.86 1.27 0.70 1.18 1.28 1.37 1.41 1.64 1.65 1.58 1.97
Enterprise Value to Revenue (EV/Rev)		 2.49 3.11 2.47 13.46 21.67 23.62 13.58 15.32 13.21 18.55 19.59
Enterprise Value to EBITDA (EV/EBITDA)		 6.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 24.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 30.58 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 2.12 0.00 0.00 0.00 0.00 0.00 25.74 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.06 0.90 1.21 0.41 0.86 0.88 0.90 1.48 1.74 2.30 1.86
Long-Term Debt to Equity		 0.42 0.38 0.51 0.22 0.68 0.82 0.79 1.23 1.14 1.67 1.33
Financial Leverage		 -0.03 0.10 0.02 0.02 0.33 0.68 0.65 0.90 1.31 1.61 1.61
Leverage Ratio		 2.01 2.56 2.99 2.46 2.13 2.24 2.25 2.56 3.20 3.79 3.82
Compound Leverage Factor		 -0.17 3.63 4.32 2.52 2.28 2.59 2.48 2.87 3.87 5.05 5.32
Debt to Total Capital		 51.44% 47.45% 54.81% 29.21% 46.17% 46.86% 47.46% 59.68% 63.48% 69.73% 65.07%
Short-Term Debt to Total Capital		 31.05% 27.52% 31.59% 13.72% 9.36% 3.30% 5.73% 10.25% 21.79% 19.32% 18.52%
Long-Term Debt to Total Capital		 20.38% 19.93% 23.22% 15.49% 36.81% 43.56% 41.72% 49.43% 41.69% 50.40% 46.55%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 1.43% 2.80% 3.60% 57.18% 57.33% 67.82% 78.78% 77.60% 80.89% 72.94% 74.64%
Common Equity to Total Capital		 47.13% 49.75% 41.59% 13.62% -3.50% -14.67% -26.24% -37.28% -44.36% -42.67% -39.71%
Debt to EBITDA		 6.89 -74.35 -15.14 -5.66 -5.39 -7.00 -6.60 -4.85 -9.18 -10.01 -28.98
Net Debt to EBITDA		 0.29 4.61 2.52 1.97 -4.93 -4.73 -5.14 -3.88 -7.72 -7.75 -22.92
Long-Term Debt to EBITDA		 2.73 -31.23 -6.41 -3.00 -4.30 -6.51 -5.80 -4.02 -6.03 -7.24 -20.73
Debt to NOPAT		 -377.75 -9.42 -8.30 -4.48 -5.29 -9.57 -7.72 -8.12 -9.37 -10.00 -18.83
Net Debt to NOPAT		 -15.91 0.58 1.38 1.56 -4.84 -6.47 -6.01 -6.49 -7.87 -7.74 -14.89
Long-Term Debt to NOPAT		 -149.70 -3.96 -3.52 -2.38 -4.22 -8.90 -6.79 -6.72 -6.15 -7.23 -13.47
Altman Z-Score		 0.49 0.25 -0.20 -0.12 -0.71 -0.64 -0.86 -1.14 -1.27 -1.26 -0.91
Noncontrolling Interest Sharing Ratio		 1.35% 4.01% 6.56% 57.47% 92.35% 118.67% 139.63% 167.14% 205.73% 230.70% 226.11%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.00 1.26 1.00 1.41 0.45 1.32 0.73 0.68 0.32 0.46 0.48
Quick Ratio		 0.57 0.46 0.22 0.66 0.29 0.85 0.36 0.26 0.07 0.19 0.17
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -54 96 -41 -168 -212 -140 -194 41 -12 -62 -64
Operating Cash Flow to CapEx		 -96.81% -111.55% 44.66% -5.92% -30.93% -45.55% -65.62% -57.31% -239.59% -99.27% -240.83%
Free Cash Flow to Firm to Interest Expense		 -3.97 7.48 -3.00 -24.97 -51.38 -11.15 -16.77 2.34 -0.51 -2.35 -2.94
Operating Cash Flow to Interest Expense		 -1.95 -0.87 0.30 -0.83 -6.81 -2.82 -4.87 -1.80 -1.67 -2.06 -1.32
Operating Cash Flow Less CapEx to Interest Expense		 -3.96 -1.66 -0.37 -14.93 -28.81 -9.02 -12.29 -4.94 -2.37 -4.13 -1.88
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.18 0.13 0.10 0.05 0.04 0.05 0.08 0.07 0.09 0.06 0.07
Accounts Receivable Turnover		 2.48 2.16 2.14 1.69 2.45 3.05 4.77 3.52 5.18 6.06 9.90
Inventory Turnover		 100.23 56.96 39.43 34.29 55.32 16.36 18.31 9.91 9.62 12.36 11.15
Fixed Asset Turnover		 0.72 0.52 0.44 0.19 0.13 0.10 0.17 0.14 0.16 0.10 0.13
Accounts Payable Turnover		 49.15 197.89 72.05 33.40 31.07 15.93 8.98 4.85 4.38 2.79 2.80
Days Sales Outstanding (DSO)		 147.47 168.98 170.45 216.03 148.86 119.64 76.57 103.65 70.50 60.24 36.88
Days Inventory Outstanding (DIO)		 3.64 6.41 9.26 10.64 6.60 22.31 19.94 36.84 37.95 29.52 32.75
Days Payable Outstanding (DPO)		 7.43 1.84 5.07 10.93 11.75 22.91 40.63 75.31 83.31 130.93 130.28
Cash Conversion Cycle (CCC)		 143.68 173.54 174.64 215.75 143.71 119.04 55.88 65.18 25.14 -41.17 -60.65
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 273 160 179 316 484 589 733 639 605 617 654
Invested Capital Turnover		 0.38 0.30 0.30 0.11 0.07 0.06 0.12 0.10 0.12 0.09 0.10
Increase / (Decrease) in Invested Capital		 54 -113 19 138 168 106 144 -94 -34 11 38
Enterprise Value (EV)		 234 203 125 374 617 810 1,035 1,051 1,000 976 1,290
Market Capitalization		 218 204 144 154 116 119 87 142 96 47 335
Book Value per Share		 $1.57 $1.26 $1.10 $0.49 ($0.14) ($0.78) ($1.65) ($1.04) ($1.15) ($1.20) ($1.15)
Tangible Book Value per Share		 $1.52 $1.24 $1.09 ($0.21) ($0.95) ($1.65) ($3.14) ($1.55) ($1.63) ($1.65) ($1.61)
Total Capital		 449 336 345 468 504 695 819 725 674 732 757
Total Debt		 231 159 189 137 233 326 389 433 428 511 493
Total Long-Term Debt		 92 67 80 72 185 303 342 358 281 369 353
Net Debt		 9.74 -9.89 -31 -48 213 220 303 346 359 395 390
Capital Expenditures (CapEx)		 28 10 9.19 95 91 78 86 55 16 55 12
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -44 17 4.79 -11 -13 -4.02 -12 -1.19 -54 -66 -47
Debt-free Net Working Capital (DFNWC)		 139 127 109 116 -2.37 48 12 22 -41 -15 -4.49
Net Working Capital (NWC)		 -0.93 35 0.45 52 -50 25 -35 -52 -188 -156 -145
Net Nonoperating Expense (NNE)		 11 21 21 7.25 6.60 28 32 58 29 38 28
Net Nonoperating Obligations (NNO)		 54 -17 23 -15 213 220 303 347 359 395 390
Total Depreciation and Amortization (D&A)		 24 18 15 7.95 9.45 12 16 19 18 18 21
Debt-free, Cash-free Net Working Capital to Revenue		 -47.17% 26.67% 9.44% -40.71% -45.79% -11.73% -16.36% -1.73% -71.16% -125.09% -71.69%
Debt-free Net Working Capital to Revenue		 147.72% 195.32% 215.22% 418.56% -8.33% 140.24% 16.33% 31.95% -54.34% -28.31% -6.83%
Net Working Capital to Revenue		 -0.99% 53.58% 0.90% 187.76% -173.91% 73.49% -45.31% -76.40% -248.27% -297.27% -219.86%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.09) ($0.29) ($0.34) ($0.40) ($0.61) ($0.78) ($0.98) ($5.40) ($3.20) ($0.04) ($0.01)
Adjusted Weighted Average Basic Shares Outstanding		 134.55M 130.63M 130.09M 130.18M 130.24M 130.25M 260.50M 13.11M 13.11M 131.05M 131.05M
Adjusted Diluted Earnings per Share		 ($0.09) ($0.29) ($0.34) ($0.40) ($0.61) ($0.78) ($0.98) ($5.40) ($3.20) ($0.04) ($0.01)
Adjusted Weighted Average Diluted Shares Outstanding		 134.55M 130.63M 130.09M 130.18M 130.24M 130.25M 260.50M 13.11M 13.11M 131.05M 131.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($0.34) ($0.40) ($0.61) ($0.78) ($0.98) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 132.99M 130.09M 130.09M 130.10M 130.24M 131.05M 131.05M 26.05M 26.05M 260.50M 260.50M
Normalized Net Operating Profit after Tax (NOPAT)		 1.85 -11 -20 -30 -36 -33 -50 -53 -46 -51 -24
Normalized NOPAT Margin		 1.97% -16.54% -38.76% -107.74% -127.47% -96.52% -66.07% -77.69% -60.31% -97.02% -36.38%
Pre Tax Income Margin		 -0.85% -44.96% -76.71% -117.99% -197.15% -198.04% -108.99% -177.53% -103.39% -174.39% -81.07%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.69 -1.61 -1.96 -4.77 -12.77 -4.70 -6.50 -6.22 -2.77 -2.60 -1.76
NOPAT to Interest Expense		 -0.04 -1.32 -1.65 -4.53 -10.67 -2.72 -4.35 -3.05 -1.96 -1.93 -1.20
EBIT Less CapEx to Interest Expense		 -1.32 -2.40 -2.62 -18.86 -34.78 -10.90 -13.92 -9.36 -3.47 -4.68 -2.31
NOPAT Less CapEx to Interest Expense		 -2.06 -2.11 -2.31 -18.62 -32.67 -8.92 -11.77 -6.20 -2.65 -4.00 -1.75
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% -107.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -24.88% -118.49% -50.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Concord Medical Services

No quarterly metrics and ratios for Concord Medical Services are available.


Financials Breakdown Chart

Concord Medical Services Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Concord Medical Services' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Concord Medical Services' net income appears to be on an upward trend, with a most recent value of -$54.26 million in 2025, rising from -$12.07 million in 2015. The previous period was -$89.33 million in 2024. Check out Concord Medical Services' forecast to explore projected trends and price targets.

Concord Medical Services' total operating income in 2025 was -$37.39 million, based on the following breakdown:
  • Total Gross Profit: $3.69 million
  • Total Operating Expenses: $41.08 million

Over the last 10 years, Concord Medical Services' total revenue changed from $93.86 million in 2015 to $65.85 million in 2025, a change of -29.8%.

Concord Medical Services' total liabilities were at $671.70 million at the end of 2025, a 4.0% decrease from 2024, and a 104.3% increase since 2015.

In the past 10 years, Concord Medical Services' cash and equivalents has ranged from $8.19 million in 2023 to $73.91 million in 2015, and is currently $42.58 million as of their latest financial filing in 2025.

Over the last 10 years, Concord Medical Services' book value per share changed from 1.57 in 2015 to -1.15 in 2025, a change of -173.5%.


Related Companies

Financial statements for NYSE:CCM last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
SpaceX just minted 4,400 millionaires
SpaceX's $1.75 trillion IPO turned more than 4400 employees into millionaires, according to The New York Times...
The Oxford Club | Sponsoredtc pixel
The invention Elon called the greatest in history
Jeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...
Brownstone Research | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
A 50-year dollar arrangement just ended - what it means for you
In 1974, Henry Kissinger helped create the U.S.-Saudi Arabia Joint Commission on Economic Cooperation - a litt...
Golden Portfolio | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel